Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Acquired by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP boosted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 10.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 333,661 shares of the biopharmaceutical company’s stock after acquiring an additional 32,272 shares during the quarter. Dimensional Fund Advisors LP owned 0.26% of Alnylam Pharmaceuticals worth $78,520,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ALNY. Larson Financial Group LLC grew its position in shares of Alnylam Pharmaceuticals by 187.2% in the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 73 shares during the period. R Squared Ltd acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter worth about $33,000. OFI Invest Asset Management purchased a new stake in Alnylam Pharmaceuticals during the 4th quarter worth approximately $35,000. Versant Capital Management Inc raised its holdings in shares of Alnylam Pharmaceuticals by 77.6% during the fourth quarter. Versant Capital Management Inc now owns 190 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 83 shares during the last quarter. Finally, IFP Advisors Inc boosted its stake in shares of Alnylam Pharmaceuticals by 24.2% in the fourth quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company’s stock worth $57,000 after acquiring an additional 47 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Up 0.9 %

Shares of ALNY opened at $257.19 on Wednesday. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The stock has a market capitalization of $33.46 billion, a PE ratio of -118.52 and a beta of 0.30. The company’s 50-day simple moving average is $247.55 and its 200-day simple moving average is $255.64. Alnylam Pharmaceuticals, Inc. has a 1 year low of $143.81 and a 1 year high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). Analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, EVP Kevin Joseph Fitzgerald sold 663 shares of the business’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.21, for a total transaction of $169,204.23. Following the completion of the transaction, the executive vice president now owns 14,321 shares in the company, valued at approximately $3,654,862.41. The trade was a 4.42 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CMO Pushkal Garg sold 1,548 shares of the firm’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $251.67, for a total value of $389,585.16. Following the completion of the sale, the chief marketing officer now owns 11,989 shares in the company, valued at approximately $3,017,271.63. This represents a 11.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 7,392 shares of company stock valued at $1,875,627. Insiders own 1.50% of the company’s stock.

Analyst Upgrades and Downgrades

ALNY has been the subject of several recent research reports. Citigroup increased their price objective on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a “buy” rating in a research note on Friday, March 21st. Scotiabank raised their price target on shares of Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the stock a “sector outperform” rating in a research note on Monday, March 31st. Morgan Stanley dropped their price objective on shares of Alnylam Pharmaceuticals from $284.00 to $268.00 and set an “equal weight” rating for the company in a research note on Friday, April 11th. Chardan Capital reissued a “buy” rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. Finally, Sanford C. Bernstein dropped their price target on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a research report on Tuesday, January 7th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and twenty-two have assigned a buy rating to the company. According to MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $315.58.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.